Aligos Therapeutics (ALGS) shareholders approve ESPP changes and annual say-on-pay
Rhea-AI Filing Summary
Aligos Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders and an amendment to its 2020 Employee Stock Purchase Plan (ESPP). Stockholders approved adding 500,000 shares for issuance under the Amended ESPP and removing its automatic “evergreen” annual share increase feature, fixing the total share reserve.
Two Class III directors, Bridget Martell and Carole Nuechterlein, were elected to serve until the 2029 annual meeting. Stockholders ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026. They also approved, on an advisory basis, the compensation of named executive officers and chose to hold future advisory “say-on-pay” votes every year. The record date for the meeting covered 5,388,223 shares of voting common stock outstanding.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
ESPP additional reserve: 500,000 shares
Shares entitled to vote: 5,388,223 shares
Votes for Martell: 2,092,164 votes
+4 more
7 metrics
ESPP additional reserve
500,000 shares
Additional shares reserved for issuance under the Amended ESPP
Shares entitled to vote
5,388,223 shares
Voting common stock outstanding as of April 27, 2026 record date
Votes for Martell
2,092,164 votes
Votes for election of director Bridget Martell, M.A., M.D.
Votes for Nuechterlein
2,086,481 votes
Votes for election of director Carole Nuechterlein, J.D.
Auditor ratification votes for
3,786,255 votes
Votes for ratifying Ernst & Young LLP as auditor for 2026
Say-on-pay votes for
2,074,434 votes
Advisory approval of named executive officer compensation
Annual say-on-pay frequency votes
2,077,884 votes
Votes favoring one-year frequency for future advisory pay votes
Key Terms
2020 Employee Stock Purchase Plan, evergreen provision, broker non-votes, non-binding, advisory basis, +1 more
5 terms
2020 Employee Stock Purchase Plan financial
"an amendment (the “ESPP Amendment”) to the Company’s 2020 Employee Stock Purchase Plan (the “ESPP”)"
evergreen provision financial
"eliminate the “evergreen” provision in the ESPP, which currently provides for automatic annual increases"
An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.
broker non-votes financial
"As a routine proposal under applicable rules, no broker non-votes were recorded"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding, advisory basis financial
"The approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers"
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.
independent registered public accounting firm financial
"as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
FAQ
What did Aligos Therapeutics (ALGS) stockholders approve at the 2026 annual meeting?
Aligos Therapeutics stockholders approved an amendment to the 2020 Employee Stock Purchase Plan, electing directors, ratifying Ernst & Young LLP as auditor, supporting executive compensation on an advisory basis, and choosing annual advisory votes on pay. These actions confirm the company’s governance and compensation framework for the coming years.
How did Aligos Therapeutics (ALGS) change its 2020 Employee Stock Purchase Plan?
Stockholders approved reserving an additional 500,000 shares for issuance under the Amended ESPP and eliminated the plan’s “evergreen” provision that had allowed automatic annual share reserve increases through 2030. The share reserve is now a fixed number rather than automatically increasing over time.
Which directors were elected at the Aligos Therapeutics (ALGS) 2026 annual meeting?
Stockholders elected Bridget Martell, M.A., M.D., and Carole Nuechterlein, J.D., as Class III directors to serve until the 2029 annual meeting or until their successors are duly elected and qualified. Both nominees received more votes for than withheld, with additional broker non-votes reported.
What auditor did Aligos Therapeutics (ALGS) stockholders ratify for 2026?
Stockholders ratified Ernst & Young LLP as Aligos Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received 3,786,255 votes for, 7,484 votes against, and 135 abstentions, with no broker non-votes as it was a routine matter.
How often will Aligos Therapeutics (ALGS) hold future say-on-pay votes?
Stockholders approved, on an advisory basis, holding future advisory votes on named executive officer compensation every year. The one-year frequency option received 2,077,884 votes, compared with smaller support for two- and three-year options, and the company adopted the annual schedule accordingly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
